Novartis Halts Clinical Trials Following Patient Deaths

(MENAFN- Swissinfo) At the end of August, Novartis halted several clinical trials of experimental cell therapies for autoimmune diseases in the fields of immunology and neuroscience, following the deaths of three patients. This content was published on September 1, 2026 - 17:42 1 minute Keystone-SDA

Italiano it Novartis interrompe studi clinici dopo decessi di pazienti Original Read more: Novartis interrompe studi clinici dopo decessi di paz

The Basel-based pharmaceutical giant confirmed the news to the AWP news agency, which had initially been reported by the US newspaper The Wall Street Journal (WSJ), stating that the decision to suspend the programmes in question“follows the reporting of three cases of immune effector cell-associated haemophagocytic syndromes, the complications of which proved fatal”.

More More Healthcare innovation AI's next pharma challenge: tackling costly and risky clinical trials

This content was published on May 29, 2026 Drug companies are betting AI can fix the slow, expensive process of testing new drugs in humans.

Read more: AI's next pharma challenge: tackling costly and risky clinical t

MENAFN01092026000210011054ID1111608197